v3.26.1
Fair Value Measurements - Narrative (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Debt Instrument [Line Items]          
Asset impairment charges     $ 0   $ 0
Contingent consideration obligations $ 273,500,000   273,500,000   $ 246,400,000
Contingent consideration related to the acquisition of Apellis 4,100,000 $ 0 4,100,000 $ 0  
Apellis Pharmaceuticals, Inc.          
Debt Instrument [Line Items]          
Contingent consideration related to the acquisition of Apellis $ 4,100,000   $ 4,100,000    
Minimum | Human Immunology Biosciences | Measurement Input, Probability Rate          
Debt Instrument [Line Items]          
Discount rate 0.750   0.750    
Maximum | Human Immunology Biosciences | Phase 3 Clinical Trial, Felzartamab AMR          
Debt Instrument [Line Items]          
Contingent consideration obligations   $ 150,000,000.0   $ 150,000,000.0  
Maximum | Human Immunology Biosciences | Measurement Input, Probability Rate          
Debt Instrument [Line Items]          
Discount rate 0.950   0.950